Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) just unveiled an announcement.
On September 8, 2025, Shuttle Pharmaceuticals Holdings, Inc. appointed Adam Chambers as a director. Chambers is the principal of Bowery Consulting Group Inc., which is involved in a revolving loan agreement and a consulting services agreement with the company. His appointment is not based on any family relationships or material interests in transactions requiring disclosure.
Spark’s Take on SHPH Stock
According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.
Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.
To see Spark’s full report on SHPH stock, click here.
More about Shuttle Pharmaceuticals Holdings, Inc.
Average Trading Volume: 136,515
Technical Sentiment Signal: Sell
Current Market Cap: $3.61M
Find detailed analytics on SHPH stock on TipRanks’ Stock Analysis page.